Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | MET | P08581 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | PIM1 | P11309 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.66 |
| ▸ | LTK | P29376 | 1/20 | 0.66 |
| ▸ | GRK5 | P34947 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16090319 | 0.82 | GRIA1 (0.53) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL5873863 | 0.81 | KDR (1.00) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16090320 | 0.80 | CRBN (0.45) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL16090345 | 0.73 | CDK5 (0.67) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL869242 | 0.72 | GAA (0.51) | GAAUSP1USP19WDR48ELANE | |
| SCHEMBL30239369 | 0.71 | LRRK2 (0.68) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL13854137 | 0.71 | ABL1 (0.74) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL272772 | 0.70 | NPC1 (0.50) | GAAUSP1USP19WDR48ELANE | |
| SCHEMBL3141083 | 0.70 | ABL1 (0.76) | ABL1CHEK1AURKADAPK3PRKD3 | |
| SCHEMBL5873962 | 0.70 | ABL1 (0.67) | ABL1CHEK1AURKADAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | ABL1 1585/4885CHEK1 3053/4885AURKA 2089/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | ABL1 3841/4885CHEK1 4607/4885AURKA 3919/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | ABL1 1585/4885CHEK1 3053/4885AURKA 2089/4885 |
| US-20210188826-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | ABL1 1585/4885CHEK1 3053/4885AURKA 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.